BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 180 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,417,661 | -0.1% | 167,526 | -34.8% | 0.01% | -21.4% |
| Q2 2023 | $4,422,086 | +7.7% | 257,098 | +3.8% | 0.01% | -17.6% |
| Q1 2023 | $4,104,677 | +1365.6% | 247,568 | +573.6% | 0.02% | +1600.0% |
| Q4 2022 | $280,065 | -90.1% | 36,754 | -87.1% | 0.00% | -92.9% |
| Q3 2022 | $2,840,000 | +161.3% | 285,666 | +138.7% | 0.01% | +133.3% |
| Q2 2022 | $1,087,000 | -25.2% | 119,693 | -16.4% | 0.01% | 0.0% |
| Q1 2022 | $1,453,000 | -1.6% | 143,182 | +61.8% | 0.01% | +50.0% |
| Q4 2021 | $1,476,000 | -29.3% | 88,471 | +98.5% | 0.00% | -33.3% |
| Q3 2021 | $2,089,000 | -18.2% | 44,575 | +6.4% | 0.01% | -40.0% |
| Q2 2021 | $2,553,000 | +87.3% | 41,883 | +89.3% | 0.01% | +25.0% |
| Q1 2021 | $1,363,000 | -5.7% | 22,128 | +8.9% | 0.01% | -27.3% |
| Q4 2020 | $1,445,000 | +147.0% | 20,322 | +30.3% | 0.01% | +37.5% |
| Q3 2020 | $585,000 | +3.5% | 15,595 | -10.0% | 0.01% | -11.1% |
| Q2 2020 | $565,000 | – | 17,336 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |